Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alvocidib and Irinotecan in p53 Wild Type Gastric Adenocarcinoma
NCT00991952Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Sep 2009
- Primary completion
- Feb 2012
- Countries
- 1
01
Overview
A Phase 2 trial of alvocidib in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by National Cancer Institute. Started Sep 2009; status: completed.
02
Drugs
alvocidib
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT00991952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00991952.